TD Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-142,396
| Closed | -$9.09M | – | 1247 |
|
|
2025
Q1 | $9.09M | Hold |
142,396
| – | – | 0.01% | 656 |
|
|
2024
Q4 | $17.3M | Hold |
142,396
| – | – | 0.02% | 535 |
|
|
2024
Q3 | $17.7M | Sell |
142,396
-16,686
| -10% | -$2.31M | 0.02% | 533 |
|
|
2024
Q2 | $25.1M | Sell |
159,082
-17,490
| -10% | -$2.25M | 0.02% | 427 |
|
|
2024
Q1 | $22.9M | Sell |
176,572
-30,540
| -15% | -$3.74M | 0.02% | 461 |
|
|
2023
Q4 | $20M | Buy |
207,112
+2,486
| +1% | +$238K | 0.02% | 476 |
|
|
2023
Q3 | $24.8M | Buy |
204,626
+161,788
| +378% | +$18.3M | 0.03% | 391 |
|
|
2023
Q2 | $4.91M | Sell |
42,838
-16,300
| -28% | -$2.1M | 0.01% | 746 |
|
|
2023
Q1 | $8.15M | Buy |
59,138
+18,916
| +47% | +$2.45M | 0.01% | 637 |
|
|
2022
Q4 | $5.21M | Sell |
40,222
-1,035
| -3% | -$120K | 0.01% | 743 |
|
|
2022
Q3 | $4.52M | Sell |
41,257
-2,978
| -7% | -$300K | 0.01% | 780 |
|
|
2022
Q2 | $3.32M | Buy |
44,235
+1,700
| +4% | +$125K | ﹤0.01% | 861 |
|
|
2022
Q1 | $3.32M | Buy |
42,535
+14,800
| +53% | +$1.13M | ﹤0.01% | 929 |
|
|
2021
Q4 | $2.5M | Hold |
27,735
| – | – | ﹤0.01% | 1078 |
|
|
2021
Q3 | $2.56M | Hold |
27,735
| – | – | ﹤0.01% | 1011 |
|
|
2021
Q2 | $1.88M | Sell |
27,735
-14,086
| -34% | -$1.07M | ﹤0.01% | 1116 |
|
|
2021
Q1 | $3.12M | Sell |
41,821
-2,528
| -6% | -$233K | ﹤0.01% | 961 |
|
|
2020
Q4 | $7.56M | Sell |
44,349
-2,855
| -6% | -$423K | 0.01% | 676 |
|
|
2020
Q3 | $6.63M | Buy |
47,204
+5,889
| +14% | +$895K | 0.01% | 639 |
|
|
2020
Q2 | $6.62M | Buy |
41,315
+3,822
| +10% | +$520K | 0.01% | 594 |
|
|
2020
Q1 | $3.67M | Sell |
37,493
-41,500
| -53% | -$4.74M | 0.01% | 688 |
|
|
2019
Q4 | $10.2M | Sell |
78,993
-14,196
| -15% | -$1.43M | 0.01% | 544 |
|
|
2019
Q3 | $7.02M | Buy |
93,189
+1,008
| +1% | +$119K | 0.01% | 611 |
|
|
2019
Q2 | $14M | Buy |
92,181
+9,300
| +11% | +$1.13M | 0.02% | 440 |
|
|
2019
Q1 | $9.88M | Sell |
82,881
-11,582
| -12% | -$1.49M | 0.02% | 522 |
|
|
2018
Q4 | $10.3M | Buy |
94,463
+6,800
| +8% | +$850K | 0.02% | 482 |
|
|
2018
Q3 | $14.2M | Sell |
87,663
-6,837
| -7% | -$935K | 0.02% | 459 |
|
|
2018
Q2 | $12.5M | Buy |
94,500
+23,600
| +33% | +$2.23M | 0.02% | 475 |
|
|
2018
Q1 | $5.25M | Buy |
70,900
+33,800
| +91% | +$2.25M | 0.01% | 661 |
|
|
2017
Q4 | $2.06M | Buy |
37,100
+17,700
| +91% | +$938K | ﹤0.01% | 880 |
|
|
2017
Q3 | $880K | Buy |
19,400
+9,900
| +104% | +$396K | ﹤0.01% | 1062 |
|
|
2017
Q2 | $320K | Sell |
9,500
-4,800
| -34% | -$156K | ﹤0.01% | 1251 |
|
|
2017
Q1 | $423K | Sell |
14,300
-900
| -6% | -$27.9K | ﹤0.01% | 1248 |
|
|
2016
Q4 | $417K | Sell |
15,200
-5,600
| -27% | -$225K | ﹤0.01% | 1230 |
|
|
2016
Q3 | $1.28M | Buy |
+20,800
| New | +$629K | ﹤0.01% | 962 |
|
|
2013
Q3 | – | Sell |
-17,600
| Closed | -$670K | – | 1272 |
|
|
2013
Q2 | $670K | Buy |
+17,600
| New | +$629K | ﹤0.01% | 890 |
|
Other funds holding SRPT
EAM
TD Asset Management's SRPT Position: Q2 2025 in Review
TD Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 142,396 shares — an estimated $9.09M sold.
TD Asset Management first reported a position in SRPT in Q2 2013 and held it in 36 quarters. The position peaked at $25.1M in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.
- TD Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
- TD Asset Management sold 142,396 Sarepta Therapeutics shares in Q2 2025, an estimated $9.09M.
- TD Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 36 quarters.
- TD Asset Management's Sarepta Therapeutics position peaked at $25.1M in Q2 2024.
- 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.
Based on TD Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.